Conditions for the Generation of Cytotoxic CD4(+) Th Cells That Enhance CD8(+) CTL-mediated Tumor Regression
Overview
Affiliations
Adoptive cell therapies (ACTs) using tumor-reactive T cells have shown clinical benefit and potential for cancer treatment. While the majority of the current ACT are focused on using CD8(+) cytotoxic T lymphocytes (CTL), others have shown that the presence of tumor-reactive CD4(+) T helper (Th) cells can greatly enhance the anti-tumor activity of CD8(+) CTL. However, difficulties in obtaining adequate numbers of CD4(+) Th cells through in vitro expansion can limit the application of CD4 Th cells in ACT. This study aims to optimize the culture conditions for mouse CD4 T cells to provide basic information for animal studies of ACT using CD4 T cells. Taking advantage of the antigen-specificity of CD4(+) Th cells from OT-II transgenic mice, we examined different methodologies for generating antigen-specific CD4(+) Th1 cells in vitro. We found that cells grown in complete advanced-DMEM/F12 medium supplemented with low-dose IL-2 and IL-7 induced substantial cell expansion. These Th cells were Th1-like, as they expressed multiple Th1-cytokines and exhibited antigen-specific cytotoxicity. In addition co-transfer of these CD4(+) Th1-like cells with CD8(+) CTL significantly enhanced tumor regression, leading to complete cure in 80% of mice bearing established B16-OVA. These observations indicate that the CD4(+) Th1-like cells generated using the method we optimized are functionally active to eliminate their target cells, and can also assist CD8(+) CTL to enhance tumor regression. The findings of this study provide valuable data for further research into in vitro expansion of CD4(+) Th1-like cells, with potential applications to cancer treatment involving ACT.
Ji W, Wang W, Wei Y Am J Cancer Res. 2023; 13(11):5218-5235.
PMID: 38058799 PMC: 10695788.
Yuan C, Huang J, Li H, Zhai R, Zhai J, Fang X Front Surg. 2023; 10:1102545.
PMID: 37206348 PMC: 10188938. DOI: 10.3389/fsurg.2023.1102545.
Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy.
Castro-Sanchez P, Teagle A, Prade S, Zamoyska R Front Cell Dev Biol. 2021; 8:608747.
PMID: 33425916 PMC: 7793860. DOI: 10.3389/fcell.2020.608747.
Wang X, Li J, Liu D, Zhang L, Zhao B, Tang J Int J Clin Exp Pathol. 2020; 11(4):2201-2213.
PMID: 31938332 PMC: 6958188.
LaBelle C, Zhang R, Armistead P, Allbritton N IEEE Trans Biomed Eng. 2019; 67(8):2166-2175.
PMID: 31794384 PMC: 7247929. DOI: 10.1109/TBME.2019.2956081.